Savaria (TSE:SIS – Get Free Report) had its target price lifted by stock analysts at Raymond James Financial from C$27.00 to C$32.00 in a report released on Friday,BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock. Raymond James Financial’s price objective would suggest a potential upside of 25.39% from the stock’s previous close.
A number of other analysts have also recently commented on the stock. National Bank Financial boosted their target price on shares of Savaria from C$30.00 to C$30.50 and gave the company an “outperform” rating in a report on Friday. Scotiabank increased their price target on shares of Savaria from C$25.00 to C$26.00 in a research note on Monday, November 10th. Stifel Nicolaus lifted their price target on shares of Savaria from C$28.00 to C$29.00 and gave the company a “buy” rating in a research report on Friday. Desjardins boosted their price objective on shares of Savaria from C$27.00 to C$32.00 and gave the stock a “buy” rating in a research note on Friday. Finally, TD Securities upped their price objective on shares of Savaria from C$27.00 to C$31.00 and gave the stock a “buy” rating in a report on Thursday. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Savaria presently has a consensus rating of “Buy” and an average price target of C$30.93.
Check Out Our Latest Report on SIS
Savaria Trading Down 3.4%
Savaria (TSE:SIS – Get Free Report) last issued its quarterly earnings results on Wednesday, March 4th. The company reported C$0.37 earnings per share for the quarter. The company had revenue of C$241.78 million for the quarter. Savaria had a return on equity of 11.10% and a net margin of 7.53%. Equities research analysts predict that Savaria will post 1.2048518 earnings per share for the current fiscal year.
Trending Headlines about Savaria
Here are the key news stories impacting Savaria this week:
- Positive Sentiment: Multiple brokerages raised price targets and upgraded ratings this morning (ATB Cormark to C$32, Raymond James to C$32, National Bank to C$30.50, Scotiabank to C$30, Desjardins to C$32, Stifel and TD also higher). These raises signal stronger analyst confidence and imply double‑digit upside from current levels. Analyst Rating Roundup
- Positive Sentiment: Savaria reported record 2025 results and stronger margins, with Q4 revenue of C$241.8M and EPS C$0.37 — results the company says position it for a new growth phase around its Savaria One strategy. This fundamental momentum underpins the analyst upgrades. Record 2025 Results
- Positive Sentiment: Coverage pieces note Savaria “entering a new growth phase” after completion of Savaria One and record Q4, reinforcing the narrative for higher future growth and margin improvement. Growth Phase Article
- Neutral Sentiment: The shares briefly hit a 12‑month high following the analyst activity and results, attracting attention from retail and institutional traders. 12‑Month High Coverage
- Neutral Sentiment: Management’s earnings release and conference call are available for review (detailed Q4 release and call transcript), useful for investors who want to assess guidance and cadence of margin improvement. Press Release / Transcript
- Negative Sentiment: Despite the positive newsflow, the stock is lower — likely reflecting short‑term profit‑taking after a run to a 52‑week high, elevated trading volume, and valuation concerns (current reported P/E ~29 and very high PEG). Those factors can pressure the share price even amid upgrades. Market Data / Valuation
Savaria Company Profile
Savaria Corporation ( savaria.com ) is a global leader in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts and elevators for home and commercial use. It also manufactures and markets a comprehensive selection of pressure management products for the medical market, medical beds for the long-term care market, as well as an extensive line of medical equipment and solutions for the safe handling of patients, including ceiling lifts and slings.
See Also
- Five stocks we like better than Savaria
- “I just bought 10,000 shares of a $5 stock…”
- 3 Signs You May Want to Switch Financial Advisors
- How JPMorgan’s $8,000 Gold Call Will Leave Most Retirement Accounts Behind
- Silver Is the New Oil—And the World’s Running Dry
- Central banks just did something they haven’t done since 1967
Receive News & Ratings for Savaria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savaria and related companies with MarketBeat.com's FREE daily email newsletter.
